https://spypharm.com/rss/latest-posts SpyPharm | Pharmaceutical News, Developments & Trends & Latest Posts en Copyright 2023 Spypharm & All Rights Reserved. https://spypharm.com/roche-partners-with-transcription-factor-pioneer-flare-in-over-18b-cancer-deal https://spypharm.com/roche-partners-with-transcription-factor-pioneer-flare-in-over-18b-cancer-deal Wed, 20 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/aha-2024-plozasiran-demonstrates-promising-phase-iii-results-in-fcs-adults https://spypharm.com/aha-2024-plozasiran-demonstrates-promising-phase-iii-results-in-fcs-adults Tue, 19 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/aha-2024-lerodalcibep-provides-promising-results-in-open-label-extension-trial-liberate-ole https://spypharm.com/aha-2024-lerodalcibep-provides-promising-results-in-open-label-extension-trial-liberate-ole Tue, 19 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/emas-chmp-to-approve-bms-opdivo-for-colorectal-cancer https://spypharm.com/emas-chmp-to-approve-bms-opdivo-for-colorectal-cancer Tue, 19 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/chmp-recommends-astrazenecas-tagrisso-for-eu-approval-for-nsclc https://spypharm.com/chmp-recommends-astrazenecas-tagrisso-for-eu-approval-for-nsclc Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/sandozs-afqlir-gains-ec-marketing-authorisation-for-retinal-diseases https://spypharm.com/sandozs-afqlir-gains-ec-marketing-authorisation-for-retinal-diseases Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/fda-approves-syndaxs-revuforj-to-treat-leukaemia https://spypharm.com/fda-approves-syndaxs-revuforj-to-treat-leukaemia Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/aha-2024-tirzepatide-improves-outcomes-for-major-heart-failure-with-hfpef-and-obesity-in-summit https://spypharm.com/aha-2024-tirzepatide-improves-outcomes-for-major-heart-failure-with-hfpef-and-obesity-in-summit Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/astrazeneca-picks-first-treg-cell-therapy-from-quell-therapeutics-partnership https://spypharm.com/astrazeneca-picks-first-treg-cell-therapy-from-quell-therapeutics-partnership Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/intellias-gene-editing-therapy-shows-early-potential-in-rare-heart-condition https://spypharm.com/intellias-gene-editing-therapy-shows-early-potential-in-rare-heart-condition Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/abbvies-elahere-wins-european-approval-for-certain-ovarian-cancers https://spypharm.com/abbvies-elahere-wins-european-approval-for-certain-ovarian-cancers Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/bavarian-nordic-shares-sink-by-12-after-mpox-sales-slump-in-q3 https://spypharm.com/bavarian-nordic-shares-sink-by-12-after-mpox-sales-slump-in-q3 Sun, 17 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/fda-reviews-sanofi-and-regenerons-dupixent-label-expansion-for-urticaria https://spypharm.com/fda-reviews-sanofi-and-regenerons-dupixent-label-expansion-for-urticaria Sun, 17 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/ac-immunes-stock-jumps-after-parkinsons-therapy-shows-signs-of-benefit https://spypharm.com/ac-immunes-stock-jumps-after-parkinsons-therapy-shows-signs-of-benefit Sun, 17 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/fda-approves-azurity-pharmaceuticals-danziten-for-cml-treatment https://spypharm.com/fda-approves-azurity-pharmaceuticals-danziten-for-cml-treatment Sun, 17 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/fda-to-lift-hold-over-novavax-flu-shot-program https://spypharm.com/fda-to-lift-hold-over-novavax-flu-shot-program Sat, 16 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/jj-medtech-gets-fda-nod-for-varipulse-pfa-system https://spypharm.com/jj-medtech-gets-fda-nod-for-varipulse-pfa-system Sat, 16 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/bad-news-for-abbvie-as-emraclidine-fails-to-perform-in-trials https://spypharm.com/bad-news-for-abbvie-as-emraclidine-fails-to-perform-in-trials Sat, 16 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/kronos-mulls-strategic-alternatives-after-axing-cancer-drug-development https://spypharm.com/kronos-mulls-strategic-alternatives-after-axing-cancer-drug-development Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints https://spypharm.com/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/metsera-raises-215m-in-series-b-round-for-weight-loss-candidates https://spypharm.com/metsera-raises-215m-in-series-b-round-for-weight-loss-candidates Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/fda-grants-accelerated-approval-for-ptcs-aadc-deficiency-gene-therapy https://spypharm.com/fda-grants-accelerated-approval-for-ptcs-aadc-deficiency-gene-therapy Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/huaweis-top-10-construction-principles-for-intelligent-computing-centre-facilities https://spypharm.com/huaweis-top-10-construction-principles-for-intelligent-computing-centre-facilities Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/msd-secures-worldwide-license-for-lanovas-lm-299 https://spypharm.com/msd-secures-worldwide-license-for-lanovas-lm-299 Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/emas-chmp-recommends-sanofis-sarclisa-approval-for-multiple-myeloma https://spypharm.com/emas-chmp-recommends-sanofis-sarclisa-approval-for-multiple-myeloma Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/trump-picks-vaccine-sceptic-rfk-jr-to-lead-hhs-in-new-administration https://spypharm.com/trump-picks-vaccine-sceptic-rfk-jr-to-lead-hhs-in-new-administration Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/ema-committee-rethinks-stance-and-recommends-leqembi-for-alzheimers-disease https://spypharm.com/ema-committee-rethinks-stance-and-recommends-leqembi-for-alzheimers-disease Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/leading-account-and-intent-based-sales-and-marketing-providers-and-technology-solutions-for-the-pharmaceutical-industry https://spypharm.com/leading-account-and-intent-based-sales-and-marketing-providers-and-technology-solutions-for-the-pharmaceutical-industry Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/nhs-launches-game-changer-and-lifesaving-anti-smoking-pill https://spypharm.com/nhs-launches-game-changer-and-lifesaving-anti-smoking-pill Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-bostongene https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-bostongene Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/pfizer-considers-divestiture-of-hospital-drugs-business https://spypharm.com/pfizer-considers-divestiture-of-hospital-drugs-business Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine https://spypharm.com/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/are-dry-powder-inhalers-the-key-to-sustainable-respiratory-care https://spypharm.com/are-dry-powder-inhalers-the-key-to-sustainable-respiratory-care Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/dmts-are-major-clinical-research-focus-for-parkinsons-disease-analysis-shows https://spypharm.com/dmts-are-major-clinical-research-focus-for-parkinsons-disease-analysis-shows Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/uppsala-and-kth-royal-develop-antibody-for-potential-cancer-treatment https://spypharm.com/uppsala-and-kth-royal-develop-antibody-for-potential-cancer-treatment Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/idweek-2024-strategic-approaches-and-challenges-in-mpox-vaccination https://spypharm.com/idweek-2024-strategic-approaches-and-challenges-in-mpox-vaccination Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/zai-lab-and-argenx-announce-nmpa-approval-for-sbla-for-vyvgart-hytrulo https://spypharm.com/zai-lab-and-argenx-announce-nmpa-approval-for-sbla-for-vyvgart-hytrulo Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/fda-grants-breakthrough-status-to-jjs-nipocalimab-for-sjd-treatment https://spypharm.com/fda-grants-breakthrough-status-to-jjs-nipocalimab-for-sjd-treatment Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/dizal-seeks-fda-approval-for-nsclc-treatment-sunvozertinib https://spypharm.com/dizal-seeks-fda-approval-for-nsclc-treatment-sunvozertinib Mon, 11 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/investment-surges-hurdles-and-emerging-innovations-in-neuroscience https://spypharm.com/investment-surges-hurdles-and-emerging-innovations-in-neuroscience Mon, 11 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/improving-life-science-rd-outcomes-with-ai https://spypharm.com/improving-life-science-rd-outcomes-with-ai Sun, 10 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/santen-arctic-vision-sign-deal-for-arvn001-to-treat-ume https://spypharm.com/santen-arctic-vision-sign-deal-for-arvn001-to-treat-ume Sat, 09 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/private-equity-deals-in-pharmaceutical-in-canada-remained-flat-in-q3-2024 https://spypharm.com/private-equity-deals-in-pharmaceutical-in-canada-remained-flat-in-q3-2024 Sat, 09 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/ultra-processed-food-is-causing-a-boom-for-obesity-drug-ozempic https://spypharm.com/ultra-processed-food-is-causing-a-boom-for-obesity-drug-ozempic Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/eisai-lowers-leqembi-revenue-forecast-after-rocky-entry-to-market https://spypharm.com/eisai-lowers-leqembi-revenue-forecast-after-rocky-entry-to-market Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/aurinia-slashes-workforce-by-45-to-focus-on-lupus-and-autoimmune-assets https://spypharm.com/aurinia-slashes-workforce-by-45-to-focus-on-lupus-and-autoimmune-assets Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/lakeshore-commences-bla-submission-to-drap-for-rabies-vaccine https://spypharm.com/lakeshore-commences-bla-submission-to-drap-for-rabies-vaccine Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/astrazeneca-and-amgens-tezspire-succeeds-in-phase-iii-nasal-polyps-trial https://spypharm.com/astrazeneca-and-amgens-tezspire-succeeds-in-phase-iii-nasal-polyps-trial Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/the-fundamentals-of-developing-parenteral-drug-products https://spypharm.com/the-fundamentals-of-developing-parenteral-drug-products Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/mustang-bios-mb-108-receives-fda-orphan-drug-status-for-glioma-treatment https://spypharm.com/mustang-bios-mb-108-receives-fda-orphan-drug-status-for-glioma-treatment Sat, 09 Nov 2024 06:00:08 -0500 spectro